{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:23:18Z","timestamp":1761060198571},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1097\/tp.0000000000001467","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T08:52:13Z","timestamp":1473929533000},"page":"996-1000","source":"Crossref","is-referenced-by-count":22,"title":["Sofosbuvir\/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation"],"prefix":"10.1097","volume":"101","author":[{"given":"Mohamed A.","family":"Elfeki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Abou Mrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamak","family":"Modaresi Esfeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizar N.","family":"Zein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijan","family":"Eghtesad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xaralambos","family":"Zervos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim A.","family":"Hanouneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naim","family":"Alkhouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20-20210211","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/liv.12779","article-title":"The outcomes of adult liver transplants in the United States from 1987 to 2013","volume":"35","author":"Stepanova","year":"2015","journal-title":"Liver Int"},{"key":"R2-20-20210211","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J Hepatol"},{"key":"R3-20-20210211","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00004836-200209000-00013","article-title":"Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States","volume":"35","author":"Hassan","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"R4-20-20210211","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1053\/jlts.2003.50248","article-title":"The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients","volume":"9","author":"Gane","year":"2003","journal-title":"Liver Transpl"},{"key":"R5-20-20210211","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0168-8278(00)80231-7","article-title":"HCV-related fibrosis progression following liver transplantation: increase in recent years","volume":"32","author":"Berenguer","year":"2000","journal-title":"J Hepatol"},{"key":"R6-20-20210211","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/lt.21635","article-title":"Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis","volume":"14","author":"Roche","year":"2008","journal-title":"Liver Transpl"},{"key":"R7-20-20210211","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/hepr.12447","article-title":"Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation","volume":"45","author":"Kawaoka","year":"2015","journal-title":"Hepatol Res"},{"key":"R8-20-20210211","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/01.TP.0000100481.14514.BB","article-title":"Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series","volume":"77","author":"Rodriguez-Luna","year":"2004","journal-title":"Transplantation"},{"key":"R9-20-20210211","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0168-8278(02)00109-5","article-title":"Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin","volume":"37","author":"Lavezzo","year":"2002","journal-title":"J Hepatol"},{"key":"R10-20-20210211","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/jlts.2002.33968","article-title":"Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy","volume":"8","author":"Narayanan Menon","year":"2002","journal-title":"Liver Transpl"},{"key":"R11-20-20210211","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/jhep.2002.36162","article-title":"A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C","volume":"36","author":"Shakil","year":"2002","journal-title":"Hepatology"},{"key":"R12-20-20210211","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/hep.510260236","article-title":"Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation","volume":"26","author":"Bizollon","year":"1997","journal-title":"Hepatology"},{"key":"R13-20-20210211","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1053\/gast.2003.50095","article-title":"Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study","volume":"124","author":"Samuel","year":"2003","journal-title":"Gastroenterology"},{"key":"R14-20-20210211","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.27681","article-title":"Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation","volume":"61","author":"Forns","year":"2015","journal-title":"Hepatology"},{"key":"R15-20-20210211","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"R16-20-20210211","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"R17-20-20210211","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N Engl J Med"},{"key":"R18-20-20210211","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1111\/liv.12856","article-title":"Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients","volume":"35","author":"Saab","year":"2015","journal-title":"Liver Int"},{"key":"R19-20-20210211","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.27770","article-title":"Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant","volume":"61","author":"Pungpapong","year":"2015","journal-title":"Hepatology"},{"key":"R21-20-20210211","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2010.09.010","article-title":"Pathogenesis of cholestatic hepatitis C","volume":"54","author":"McCaughan","year":"2011","journal-title":"J Hepatol"},{"key":"R22-20-20210211","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MOT.0000000000000288","article-title":"Perspectives on treating hepatitis C infection in the liver transplantation setting","volume":"21","author":"Chen","year":"2016","journal-title":"Curr Opin Organ Transplant"},{"key":"R23-20-20210211","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/lt.22271","article-title":"PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus","volume":"17","author":"Bzowej","year":"2011","journal-title":"Liver Transpl"},{"key":"R24-20-20210211","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.1016\/S0168-8278(15)30154-9","article-title":"Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study","volume":"62","author":"Poordad","year":"2015","journal-title":"J Hepatol"},{"key":"R25-20-20210211","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/lt.24366","article-title":"Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network","volume":"22","author":"Brown","year":"2016","journal-title":"Liver Transpl"},{"key":"R26-20-20210211","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/S0168-8278(16)01652-4","article-title":"Should we keep using ribavirin to treat hepatitis C recurrence after liver transplantation? Results from the CO23 ANRS CUPILT study","volume":"64","author":"Houssel-Debry","year":"2016","journal-title":"J Hepatol"},{"key":"R27-20-20210211","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/TP.0000000000001126","article-title":"Sofosbuvir-based antiviral therapy is highly effective in recurrent hepatitis C in liver transplant recipients: Canadian multicenter \u201creal-life\u201d experience","volume":"100","author":"Faisal","year":"2016","journal-title":"Transplantation"},{"key":"R28-20-20210211","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/tid.12524","article-title":"Efficacy and safety of sofosbuvir\/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation","volume":"18","author":"Ciesek","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"R29-20-20210211","first-page":"326","article-title":"On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial","volume":"18","author":"Welzel","year":"2016","journal-title":"Antivir Ther"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000001467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:25:55Z","timestamp":1620977155000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201705000-00020"}},"subtitle":["Two-Center Experience"],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000001467","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}